David A. Siegel Landos Biopharma, Inc. Transaction History

Two Sigma Advisers, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.67 - $1.26 $9,447 - $17,766	-14,100 Reduced 41.59%	19,800 $13,000
Q2 2022 Aug 15, 2022	SELL	$0.6 - $1.5 $5,040 - $12,600	-8,400 Reduced 19.86%	33,900 $25,000
Q1 2022 May 16, 2022	BUY	$1.44 - $5.22 $23,904 - $86,652	16,600 Added 64.59%	42,300 $62,000
Q4 2021 Feb 14, 2022	BUY	$4.7 - $15.0 $120,790 - $385,500	25,700 New	25,700 $123,000

Ticker LABP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,254,900
Description
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of u...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.